Strategic partnerships Chemomab recently merged with Scipher Medicine, highlighting a growth-through-licensing and collaboration strategy. This indicates openness to joint development and commercial partnerships with bigger players to accelerate trials, broaden indications, and expand global reach.

Phase 3 readiness Positive Phase 2 SPRING results in PSC and FDA/EMA alignment for Phase 3 suggest imminent upmarket opportunities. Sales teams can target biotech partners, CROs, and potential licensees seeking late-stage assets or co-development for regulatory filings.

Orphan disease focus Orphan Drug designations for PSC and systemic sclerosis, plus Fast Track status for PSC, create attractive pathways for faster reimbursement discussions and partner funding. Target specialty insurers, patient access programs, and rare-disease-focused distributors.

Financial runway With funding of approximately $91 million and mid-stage revenue, there is budget capacity for strategic collaborations, co-development deals, or milestone-driven partnerships. Potential sales opportunities include licensing deals, milestone-driven collaborations, and upfront payments tied to development milestones.

Engaged leadership Active participation in major conferences and ongoing C-suite leadership changes (Interim CMO appointment and new Chief Development Officer) indicate accessibility for business development discussions and clear points of contact for partnership negotiations.